Oral Kelulut honey to help itchy, red, watery and dry eyes from allergic conjunctivitis
Official title: A Randomized Controlled Trial on the Effects of Oral Kelulut Honey Supplementation on Conjunctival Goblet Cell Density, Tear Film Stability, Dry Eye Disease Symptoms and Vision-Related Function in Patients With Allergic Conjunctivitis
Run by Universiti Sains Malaysia · NCT07273747 · Data updated 2026-11-12
This trial will see if adults with allergic conjunctivitis who take daily oral Kelulut honey for one month have less itchy, red, watery eyes and dry eye symptoms than people taking a honey‑flavored placebo, and it will monitor side effects.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | All |
| Enrollment | 72 (estimated) |
| Sponsor | Universiti Sains Malaysia Academic / other |
| Locations | 1 site (Kota Bharu, Kelantan) |
| Status | Recruiting |
| Started | September 17, 2025 |
| Main results expected | January 16, 2026 |
| Study ends | September 2026 |
| Registry record updated | December 9, 2025 |
| Trial ID | NCT07273747 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–40 years old with confirmed allergic conjunctivitis, OSDI >12, and who are compliant with standard allergic conjunctivitis treatments are the intended participants.
✕Probably not a fit
People with other ocular surface diseases, diabetes, recent ocular surgery or trauma, recent contact lens wear, systemic inflammatory or connective tissue diseases, or those using excluded medications or supplements are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, placebo‑controlled interventional trial at Hospital Pakar Universiti Sains Malaysia comparing daily oral Kelulut honey (60 g or 120 g) to a honey‑flavored zero‑calorie placebo for one month. Adults aged 18–40 with confirmed allergic conjunctivitis and an OSDI score >12 will be enrolled and continue their conventional allergic conjunctivitis treatment. Outcomes include patient‑reported symptoms (OSDI, itchiness, redness, tearing), objective tear film stability measures and conjunctival goblet cell health, along with recording adverse events. The trial excludes people with other ocular surface disease, diabetes, recent eye surgery or trauma, recent contact lens use, systemic inflammatory conditions, or concurrent use of conflicting medications or supplements.
Why it matters
Potential benefit: If effective, Kelulut honey could provide a simple, low‑cost oral supplement to reduce itchiness, redness, watery and dry eye symptoms in people with allergic conjunctivitis.
How similar studies have gone: This approach is relatively novel for oral Kelulut honey and has limited clinical evidence, though some small studies of topical honey preparations have shown mixed results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: i. Age between 18-40 years old ii. Confirmed diagnosis of allergic conjunctivits iii. Ocular surface disease index (OSDI) score \> 12 iv. Compliance to conventional allergic conjunctivitis treatment Exclusion Criteria: i. Any corneal or ocular surface pathology ii. Known diabetes mellitus or impaired glucose test iii. Ocular surface disease due to trachoma or other inflammatory conditions iv. Consume anti-inflammatory medications such as steroids, NSAIDS, oral doxycycline v. Concurrent use of other supplements or alternative therapies such as royal jelly, Manuka honey eye drop or omega-3 fatty acid vi. Using preservative-containing topical eye drops for ocular problems other than AC, such as anti-glaucoma medication vii. History of ocular trauma/surgery or refractive surgery within last 3 years viii. Wearing contact lens in the last 3 months ix. Underlying inflammatory/ systemic disease and connective tissue diseases x. Recent conjunctivitis in the last 3 months xi. Patients on immunosuppressant
Where it's running
-
Hospital Pakar Universiti Sains Malaysia
Kota Bharu, Kelantan, Malaysia Recruiting
Study contacts
- Principal investigator: Shahidatul Adha Dr, MD, MMed — Universiti Sains Malaysia
- Study coordinator: Sharifah Izzati Dr, MD
- Email: shzatiee@gmail.com
- Phone: +6010-2329207
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Daydrop Triple Action for Allergic Eye Symptoms
We’re testing Daydrop Triple Action eye drops to see if they safely help relieve itching and other allergy symptoms in adults with allergic conjunctivitis.
-
Lacrifill to Help Prevent Post-Curgery Dry Eye After Cataract Surgery
This study tests Lacrifill to see if it helps prevent dry eye symptoms after unilateral cataract surgery.
-
Tear-Fluid Stability Testing with iTrace, BOSA, OPD-Scan III, and IDRA for Dry Eye
A Phase 4 study tests whether four eye devices can detect tear film stability in adults with normal tear film.
-
OT202 1% eye drops for moderate to severe dry eye
This phase 3 study tests whether 1% OT202 eye drops help people with moderate to severe dry eye better than a placebo.
-
Tyrvaya Nasal Spray for Comfort in Contact Lens Wearers
This study tests whether using Tyrvaya twice daily can improve comfort for adults who wear soft contact lenses and have dry eye symptoms.
-
Long-term effects of Acoltremon vs. control in dry eye disease
This study tests whether Acoltremon eye drops help people with dry eye over a year compared with a preservative-free artificial tear, at a single center.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.